Related Experiment Videos

Approaches toward peptide-based immunotherapy of autoimmune diseases

L Adorini¹, J C Guéry, S Trembleau

¹Sandoz Pharma Ltd., Basel, Switzerland.

Springer Seminars in Immunopathology

|January 1, 1992

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Protective effect of UDCA against IL-11- induced cardiac fibrosis is mediated by TGR5 signalling.

Frontiers in cardiovascular medicine·2024

Farnesoid X receptor activation by the novel agonist TC-100 (3α, 7α, 11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid) preserves the intestinal barrier integrity and promotes intestinal microbial reshaping in a mouse model of obstructed bile acid flow.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2022

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.

PloS one·2019

Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model.

Journal of endocrinological investigation·2019

Therapeutic effects of obeticholic acid (OCA) treatment in a bleomycin-induced pulmonary fibrosis rat model.

Journal of endocrinological investigation·2018

Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.

Biochimica et biophysica acta. Molecular basis of disease·2017

See all related articles